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In this issue of Eye, Randon et al.1 present the interesting findings of an in vivo confocal 
microscopy (IVCM) cross-sectional study in which they describe different patterns of presumed 
Meibomian Glands (MGs) abnormalities and propose a new IVCM- Meibomian Gland Dysfunction 
(MGD) classification. This research represents an interesting effort toward a personalized diagnostic and 
therapeutic approach to MGD patients. 
In the last years, we have seen an imaging revolution in the study of MGD. Technological evolution 
provided us new non- (or nearly non-) invasive tools, including infrared (IR) meibography, IVCM, and 
optical coherence tomography meibography (OCT-M).2, 3 The availability of a large amount of novel 
morphological information accompanied the recent development of our knowledge of MGs physio-
pathology and the growing awareness of the crucial role of MGs for the ocular surface health and 
disease.4, 5 
Meibography is the approach with the longest history and the highest level of evidence and IR 
meibography is an important evolution, allowing non –invasive examination, without the contact of an 
illuminating probe with the patient’s skin.6, 7 This technique, based on the high reflectivity of 
healthy MGs, allows to visualize the whole tarsal plate and to quantify the area of MGs drop-out 
(dark areas).  
Several groups used this technique to assess MGD patients and to describe MGs changes associated 
to different conditions, including aging, contact lens wear, ocular allergy, and severe inflammatory 
ocular surface diseases.6, 7  
IR meibography showed promising results a diagnostic test for MGD, with sensitivity and 
specificity of 49.3% and 64.5%, respectively, if used as a single test, and excellent diagnostic 
accuracy if used in combination with clinical and/or functional examinations.6,7 It’s increasingly 
used in clinical practice for MGD diagnosis and follow-up and it has been included in clinical trials 
as a surrogate endpoint. 
Main limitations of IR meibography are the relatively low resolution, inadequate to show micro-
anatomical details and inflammatory cells, and its two-dimensional approach, unable to provide 
depth information. Moreover, it’s still unclear the exact meaning of the “dark drop-out areas”, 
which might reflect a complete loss of MGs or loss or degeneration of lipid content within a 
relatively intact gland structure.6 
The recently developed OCT-M, using a customized system with a long coherence swept laser 
source with a wavelength of 1300 nm, seems to be able to provide interesting 3-D information, 
helping to discriminate different structural changes corresponding to the IR  “dark drop-out areas”.3, 
8, 9 However, at present, we have just preliminary data obtained with customized systems. 
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IVCM is an emerging nearly non-invasive technology that allows us to see ocular surface structures 
at the cellular level, providing images with magnification and resolution comparable to histological 
methods without significantly affecting the steady state of the target tissues.10, 11, 12 The laser 
scanning IVCM has the ability to go beyond the cornea and to examine the different components of 
the ocular surface, opening new doors for studying the physiology and pathology of this complex 
morpho-functional unit.10, 11, 12 The first confocal images of presumed MGs were published in 
November 2005 by Kobayashi et al.13 In the last years Asian and European research groups 
explored this application of IVCM,10, 11, 12 describing several quantitative parameters, with 
sensitivity and specificity for MGD diagnosis ranging from 80% to 100%,12, 14 and reporting 
quantitative and qualitative MGs changes related to several conditions, including aging, contact lens 
wear, ocular allergy, and severe ocular surface inflammatory diseases.12 Interestingly, IVCM 
provided the first in vivo evidence in humans of primary atrophic age-related MGD, in contrast with 
the “hyperkeratinization-obstruction-dilatation” theory.15 Moreover, this technology allows to 
analyze the micro-anatomy of the tissue, including the density of inflammatory cells and the 
presence of fibrosis.  
Together with the limited availability and the lack of validated and user-friendly software for images 
analysis, major limitations of IVCM are the small field of view (<0.25mm2) and the analysis purely 
based on morphology and reflectivity. The lack of tissue and cellular phenotyping raises several 
concerns on images interpretation and on the correlations between confocal and histologic findings.  
A recent research by Zhou and Robertson16 tried to compare IVCM and immunoflorescence findings. 
These authors concluded that confocal images previously reported as MGs acini should be 
interpreted as rete ridges in the eyelid dermal–epidermal junction. This hypothesis leaves many 
unanswered questions and it will require further studies in the next future. 
In conclusion, the ongoing imaging revolution in MGs assessment is teaching us a lot on these 
glands’ physio-pathology and it’s stimulating a virtuous cycle of increase of knowledge. Moreover, 
we now have some tools (as IR meibography) ready to play an important role in the diagnosis and 
follow-up of MGD patients, and new improved tools promise to help to move toward a more 
personalized approach to the patient. Finally, wider inclusion of imaging biomarkers and surrogate 
endpoints in clinical trials on MGD might be essential to obtain quicker, cheaper and more 
successful clinical studies. On the other hand, major efforts are needed and a lot of work is still to 
do to improve the validation of these tools and to avoid the potential consequences of biomarker 
misuse or of the choice of invalid surrogate endpoints.17 
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